Michael J. Morris, MD, discusses the safety and clinical activity of atezolizumab plus radium-223 dichloride in patients with second-line metastatic castration-resistant prostate cancer.
Michael J. Morris, MD, clinical director of Genitourinary Medical Oncology Service and Prostate Cancer Section head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the safety and clinical activity of atezolizumab (Tecentriq) plus radium-223 dichloride (Xofigo) in patients with second-line metastatic castration-resistant prostate cancer (mCRPC).
Morris says the most important part of the phase 1b trial results were the immunotherapy-related adverse effects (AEs) observed, some of which were significant. There were 2 grade 5 events related to atezolizumab. The AEs observed were toxicities normally seen with this type of treatment, such as autoimmune hepatitis and autoimmune myositis. There were some patients with count reductions and neutropenia, which may have been caused by radium-223.
In terms of a countervailing clinical benefit, they did not see anything unexpected with either radium-223 or atezolizumab independently, according to Morris. Radium-223 does not independently significantly decline prostate-specific antigen levels, and there was no improvement observed in that way with the addition of atezolizumab. There were 3 patients who had significant and durable radiographic responses: 1 patient’s response lasted 192 days, another’s for 275 days, and the last for 337 days.
However, these responses were out of 44 patients total. Morris explains that they didn't believe they could identify who those patients were that responded, which has frequently been a problem in terms of immunotherapy and prostate cancer. They felt the toxicity to clinical benefit ratio did not warrant pushing the combination forward.
<< View more resources and information regarding prostate cancer
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
FPI-2265 Dosing Commences in Phase 2 AlphaBreak Trial for mCRPC
May 10th 2024The first patient has been dosed in the phase 2 AlphaBreak trial with FPI-2265 for the treatment of metastatic castration-resistant prostate cancer, marking a significant milestone in advanced cancer treatment.
Read More
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen